- Theratechnologies (NASDAQ:THTX) announces results from two posters highlighting positive patient experience with Trogarzo.
- The poster included findings from 30 Trogarzo (ibalizumab-uiyk) patients to assess real-world patient experience and acceptance of IV administration.
- The survey found that 100% of patients were either very satisfied or moderately satisfied with their experience with Trogarzo (87% and 13% respectively).
- 93% of respondents either found the IV infusion process very convenient or neutral and would likely recommend Trogarzo to another patient living with HIV.
- 87% expressed very high satisfaction with the experience of receiving an infusion and seeing a healthcare professional every two weeks and, 80% were of the opinion that a touchpoint every two weeks was likely to support adherence to other HIV medications.
- The evaluation demonstrated an overall 98% compliance rate with Trogarzo based on 3,528 infusions administered to 130 patients between May 2018 and February 2021.
- Furthermore, a compliance rate with other antiretrovirals of 89% was observed among Trogarzo patients, supporting the patient survey findings.
- The results were presented at ACTHIV 2021 virtual conference being held May 20-22, 2021.